About Arch Pharmalabs Limited
Data last updated:
Arch Pharmalabs Limited is a public limited company based in Mumbai, Maharashtra, India. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 02 April 1993.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24231MH1993PLC150891. Its GSTIN is 27AACCM0306Q1ZE (Maharashtra). The company holds 10 GST registrations, of which 5 are active.
The company has an authorised share capital of ₹3,000 Cr and a paid-up capital of ₹156.48 Cr. It was formerly known as Sibra Pharmaceuticals Limited and Avant Papers Private Limited. It is led by directors including Ajit Annu Kamath (Managing Director) and Rajendra Padmanabhan Kaimal (Whole-Time Director).
Its last annual general meeting (AGM) was held on 29 December 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at Unit No. 301 302 And 303 H Wing 3rd Floor Tex Centre, Off Saki Vihar Road Chandivali Andheri East Mumbai, Maharashtra, India – 400072.
As per the financials filed for FY 2023, the company reported a revenue of ₹1,344.16 Cr, a growth of 2% compared to the previous year. For the same year it recorded a net profit of ₹122.12 Cr (net margin 9.1%) and EBITDA of ₹182.85 Cr (EBITDA margin 13.6%). Revenue has grown at a compounded annual rate (CAGR) of 27% over three years and 40% over five years.
The company has about 412 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand: Arch Pharmalabs. As per MCA filings, the company has open charges of ₹5,668.24 Cr and satisfied charges of ₹311.84 Cr on record. Court records list 325 cases involving the company, including 24 filed by the company and 292 filed against it; 56 cases are pending. The company has 10 deals on record (7 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹680.88 Cr; the latest was in March 2023. Its 10 peer companies in the Pharma industry (API Manufacturers, Contract Research) are compared by revenue, 5 larger and 5 smaller; the largest is Teva Api India Private Limited with revenue of ₹1,456.07 Cr. The company has 56 MSME Form 1 returns on record between 2012 and 2023, listing 2,332 overdue payments to 163 micro and small suppliers.
The last known website on record is archpharmalabs.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressUnit No. 301 302 And 303 H Wing 3rd Floor Tex Centre, Off Saki Vihar Road Chandivali Andheri East Mumbai, Maharashtra, India – 400072
- IndustryPharma, API Manufacturers, Pharma Contract R&D
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Arch Pharmalabs Limited
The main business activity of Arch Pharmalabs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Arch Pharmalabs Limited FY 2023 filings available
Arch Pharmalabs Limited reported revenue of ₹1,344.16 Cr (up 2% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR) of Arch Pharmalabs Limited
Revenue has grown at a compounded annual rate (CAGR) of 40% over five years, including 2% growth in the latest year. EBITDA rose 1% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Arch Pharmalabs Limited
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | ₹1,344.16 Cr | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹182.85 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹122.12 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Arch Pharmalabs Limited
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 13.6% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 9.1% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Arch Pharmalabs are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Arch Pharmalabs Limited
Arch Pharmalabs Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers, Contract Research). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Teva Api India Private Limited | ₹1,456.07 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Mumbai, Maharashtra, India |
| Dhanuka Laboratories Limited | ₹1,424.06 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | Chennai, Tamil Nadu, India |
| Avaya Industries Limited | ₹1,397.41 Cr (FY 2019) | •••• | •••• | 19.0% | •••• | Thane, Maharashtra, India |
| Harman Finochem Limited | ₹1,376.43 Cr (FY 2025) | •••• | •••• | 27.0% | •••• | Mumbai, Maharashtra, India |
| Cohance Lifesciences Limited | ₹1,362.25 Cr (FY 2024) | •••• | •••• | 0.0% | •••• | Mumbai, Maharashtra, India |
| Arch Pharmalabs Limited this company | ₹1,344.16 Cr (FY 2023) | •••• | •••• | 2.0% | •••• | Mumbai, Maharashtra, India |
| Shasun Pharmaceuticals Limited | ₹1,328.86 Cr (FY 2015) | •••• | •••• | 8.0% | •••• | Chennai, Tamil Nadu, India |
| Shilpa Medicare Limited Listed | ₹1,309.57 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Raichur, Karnataka, India |
| GVK Davix Technologies Private Limited | ₹1,300.18 Cr (FY 2021) | •••• | •••• | 24.0% | •••• | Hyderabad, Telangana, India |
| Solara Active Pharma Sciences Limited Listed | ₹1,292.08 Cr (FY 2025) | •••• | •••• | 0.0% | •••• | Thane, Maharashtra, India |
| Vasudha Pharma Chem Limited | ₹1,174.19 Cr (FY 2025) | •••• | •••• | 1.0% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Arch Pharmalabs by revenue in the Pharma industry (API Manufacturers, Contract Research), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Arch Pharmalabs Limited
Arch Pharmalabs Limited is audited by Neha C Shah & Associates for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Neha C Shah & Associates | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors and KMP of Arch Pharmalabs Limited
Arch Pharmalabs Limited currently reports 5 directors and 1 key managerial person. 26 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vikas Bijay Kedia | Company Secretary | 18 Nov 2017 | 8 Years 10 Months | As last reported |
| Sunil Mansukhlal Pitroda | Director | 02 May 2017 | 9 Years 5 Months | As last reported |
| Anshul Gupta Also directs: Finkonnect Capital Advisors LLP, Afro Connect Consultancy Services Private Limited, Yajur Veda Impex Private Limited and 1 more | Irp/Rp/Liquidator | 30 Apr 2025 | 1 Years 5 Months | As last reported |
| Ajit Annu Kamath Also directs: Vitalife Pharma Limited, Tack Commosales LLP, Arch Agro Industries Private Limited and 5 more | Managing Director | 01 Nov 2003 | 22 Years 11 Months | As last reported |
| Rajendra Padmanabhan Kaimal Also directs: Vitalife Pharma Limited, Arch Agro Industries Private Limited, Amra Renal Care Limited and 5 more | Whole-Time Director | 01 Nov 2003 | 22 Years 11 Months | As last reported |
| Ashish Mohan Ujagare Also directs: Vitalife Pharma Limited | Whole-Time Director | 14 Jun 2018 | 8 Years 4 Months | As last reported |
Ownership and Shareholding of Arch Pharmalabs Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Arch Pharmalabs Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Mar 2022 | Others | ₹32 Cr | Open |
| 20 Jul 2021 | Others | ₹5 Lakh | Open |
| 27 May 2021 | Others | ₹200 Cr | Open |
| 04 Dec 2017 | Others | ₹200 Cr | Open |
| 27 Sep 2013 | Others | ₹582.3 Cr | Open |
Total charge records: 65 View all charges
Deals & Funding of Arch Pharmalabs Limited
Arch Pharmalabs Limited has 10 deals on record (7 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹680.88 Cr; the latest was in March 2023.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2023 | Funding round | ₹149.49 Cr | Investors: Nipro Pharmapackaging India Private Limited |
| Dec 2017 | Funding round | ₹111.92 Cr | Investors: Arch Impex Private Limited , JM Financial Asset Reconstruction Company Limited , Arch Pharmachem Ltd |
| Nov 2017 | Acquisition | Undisclosed | Buyer: Neuland Laboratories Ltd. Seller: Arch Pharmalabs Limited |
| Oct 2015 | Funding round | ₹12.16 Cr | Investors: Arch Agro Industries Private Limited |
| Oct 2012 | Funding round | ₹150 Cr | Investors: A M R Investments Private Limited |
Full deal history
All 10 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Arch Pharmalabs Limited
Arch Pharmalabs Limited has 325 court cases on record: 24 filed by Arch Pharmalabs, 292 filed against it, 9 where it is another party. 56 cases are pending and 269 are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 226 | 217 | 34 |
| High courts | 85 | 61 | 13 |
| NCLAT | 14 | 14 | 9 |
Cases on record (5 of 325)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLAT, New Delhi | Interim or miscellaneous application | Filed against the company by Krishna Solvechem Limited | Pending |
| NCLAT, New Delhi | Interim or miscellaneous application | Filed against the company by Omkara Assets Reconstruction Private Limited | Pending |
| NCLAT, New Delhi | Interim or miscellaneous application | Filed against the company by JM Financial Asset Reconstruction Company Limited | Pending |
| NCLAT, New Delhi | Insolvency matter | Filed against the company by Krishna Solvechem Limited | Pending |
| NCLAT, New Delhi | Court case (Caveat) | Filed against the company by Krishna Solvechem Limited | Pending |
Full case history
All 325 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Arch Pharmalabs Limited
Arch Pharmalabs Limited has 56 MSME Form 1 returns on record between 2012 and 2023, listing 2,332 overdue payments to 163 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 163)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Simson Pharma Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 56 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Arch Pharmalabs Limited
Arch Pharmalabs operates one associated brand: Arch Pharmalabs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| API manufacturer & supplier, also offering custom synthesis and contract manufacturing services | archpharmalabs.com |
Employees and EPFO Compliance at Arch Pharmalabs Limited
Arch Pharmalabs Limited has a workforce of 412 employees as of Apr 08, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Arch Pharmalabs Limited
Arch Pharmalabs has 3 subsidiary companies and 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Arch Finechemicals Limited | U24110TG1993PLC015533 | Locked |
| Arch Life Sciences Limited | U24239TG2003PLC042232 | Locked |
| Vitalife Pharma Limited | U24299MH2021PLC356633 | Locked |
Showing major subsidiaries. Total: 3.
Name History of Arch Pharmalabs Limited
Arch Pharmalabs has undergone 3 name changes throughout its history. The company was previously known as Sibra Pharmaceuticals Limited, Avant Papers Private Limited, and Arch Commerz Limited. The current legal name is Arch Pharmalabs Limited.
| Company Name | Status |
|---|---|
| Arch Pharmalabs Limited | Current |
| Sibra Pharmaceuticals Limited | Previous |
| Avant Papers Private Limited | Previous |
| Arch Commerz Limited | Previous |
CIN History of Arch Pharmalabs Limited
Arch Pharmalabs has one previous CIN (Corporate Identification Number): U24231MH2005PTC150891. The current CIN is U24231MH1993PLC150891, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231MH1993PLC150891 | Current |
| U24231MH2005PTC150891 | Previous |
Recent Activity on Arch Pharmalabs Limited
Arch Pharmalabs Limited has 32 board changes on record since 2003: 6 appointments and 26 cessations. The latest: Anshul Gupta was appointed as Irp/Rp/Liquidator on 30 Apr 2025.
151 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Arch Pharmalabs Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Arch Pharmalabs Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Arch Pharmalabs Limited
Arch Pharmalabs has 10 GST registrations: 5 active and 5 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCM0306Q1ZE | Maharashtra | Active | 01 Jul 2017 |
| 27AACCM0306Q2ZD | Maharashtra | Active | 01 Apr 2020 |
| 27AACCM0306Q3ZC | Maharashtra | Active | 17 Apr 2025 |
| 06AACCM0306Q1ZI | Haryana | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Arch Pharmalabs Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Arch Pharmalabs Limited
Frequently Asked Questions about Arch Pharmalabs Limited
Arch Pharmalabs is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.
Arch Pharmalabs is a company under insolvency, formerly operating as a public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 02 April 1993 and is registered under CIN U24231MH1993PLC150891. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Arch Pharmalabs reported revenue of ₹1,344.16 Cr for FY 2023 (up 2% YoY).
Arch Pharmalabs has 6 current directors and KMP:
- Ajit Annu Kamath - Managing Director
- Rajendra Padmanabhan Kaimal - Whole-Time Director
- Ashish Mohan Ujagare - Whole-Time Director
- Sunil Mansukhlal Pitroda - Director
- Vikas Bijay Kedia - Company Secretary
- Anshul Gupta - Irp/Rp/Liquidator
Arch Pharmalabs reported a net profit of ₹122.12 Cr (net margin 9.1%) and EBITDA of ₹182.85 Cr (EBITDA margin 13.6%) for FY 2023, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Arch Pharmalabs is 27% over three years and 40% over five years. In the latest year (FY 2023) revenue rose 2%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Arch Pharmalabs is U24231MH1993PLC150891. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Arch Pharmalabs has open charges of ₹5,668.24 Cr and satisfied charges of ₹311.84 Cr as per latest MCA filings.
Arch Pharmalabs has 325 court cases on record: 24 filed by the company and 292 filed against it. 56 are pending. Most are in the district courts.
Arch Pharmalabs was incorporated on 02 April 1993. It is registered with the Registrar of Companies, Mumbai.
Arch Pharmalabs has 10 deals on record (7 funding rounds, 1 rights issue, 1 secondary share transfer), with disclosed funding of ₹680.88 Cr; the latest was in March 2023.
The peers of Arch Pharmalabs by revenue are Teva Api India Private Limited, Dhanuka Laboratories Limited, Avaya Industries Limited, Harman Finochem Limited, Cohance Lifesciences Limited and 5 more, all in the Pharma industry (API Manufacturers, Contract Research).